NY-PYRAMID-ANALYTICS
30.11.2022 09:01:54 CET | Business Wire | Press release
Pyramid Analytics (Pyramid), a pioneering decision intelligence platform provider, continues to consistently execute on its strategy to rapidly expand channel partnerships with complementary technology companies, independent software vendors (ISV), consulting firms, value-added resellers (VAR) and systems integrators (SI) across the United Kingdom and Ireland (UKI). The London-based software company today announced new partnerships with Datazed Associates, Data Reply, and Digital Data Consultancy.
Key Points:
- Pyramid Analytics signed deals with new partners serving the IT needs of mid-size and large enterprises across the UKI: Datazed Associates (Referral Partner); Digital Data Consultancy (Systems Integrator); and Data Reply (Consultancy, Systems Integrator).
- The channel partner programme is the backbone of Pyramid’s UKI operations, accounting for a significant segment of UK revenue.
- Pyramid Analytics is recognized for channel excellence. The company was a CRN Channel Awards 2022 finalist.
- To learn more about becoming a Pyramid partner in the UK and Ireland, contact Bill Clayton, Vice President, Global Partnerships, at bill.clayton@pyramidanalytics.com.
Meet Pyramid Analytics’ New Partners
Datazed Associates is a boutique data consultancy specialising in data governance and data quality. The company’s network of experienced professionals has a strong track record in the insurance industry, having supported general insurers, Lloyd’s market firms, brokers and reinsurers.
Data Reply is the Reply group company offering a broad range of advanced analytics and AI-powered data services. Data Reply operates across industries and business functions to achieve meaningful outcomes through effective use of data.
Digital Data Consultancy provides consulting services in the areas of data management, data science, and digital experience. The company helps clients in retail, hospitality, healthcare, banking and consumer goods to master and reimagine their data, create new value, and differentiate and profit in the digital economy.
Pyramid Analytics Delivers Value for Partners
Partnerships are critical to Pyramid’s ability to scale growth. In turn, partners get access to the Pyramid Decision Intelligence Platform, an innovative augmented analytics platform which has garnered analyst accolades for its ability to transform businesses.
Pyramid Partners benefit from a range of resources to help them effectively market, sell, and deliver the Pyramid Platform, integrated solutions, and services. These include the Pyramid Partner Portal, a one-stop shop for deal management, market education content, co-branded marketing materials, and interactive tools and resources; and the Pyramid Learning Hub for self-guided and expert-led courses, and Pyramid Partner Certification programs.
United Kingdom the World’s “Next Silicon Valley”?
Jeremy Hunt, the UK’s Chancellor of the Exchequer, outlined a number of priorities in his Autumn Statement on 17 November. These included his plan to “turn the United Kingdom into the world’s next Silicon Valley.” Pyramid Analytics has operated and flourished in the UK for nearly five years and are proud of the company’s contribution to achieving this goal. The advanced analytics platform company has added three executives and numerous business development roles in its London office in 2022.
2022 has been momentous for Pyramid Analytics in the UKI:
- Pyramid executives, customers, partners, media and technology industry analysts celebrated a $120 million Series E funding round at a special event at Tower Bridge in May.
- Tom Warren, a veteran technology professional and former professional rugby player, was appointed Managing Director for the company’s UKI operations.
- Bill Clayton joined Pyramid in the new role of Vice President, Global Partnerships. He has more than 20 years of enterprise software experience. Clayton has held positions with global technology leaders including IBM and Oracle. He lives in the UK.
- Hayley Munro was appointed Vice President of Global Customer Success. This newly created role provides unified, company-wide management of this critical function under one executive. She lives in the UK.
Decision Intelligence is the Next Big Data Analytics Innovation
The next major innovation in analytics is Artificial Intelligence (AI). Applying AI across Data Prep, Business Analytics, and Data Science is what separates Decision Intelligence from traditional business intelligence tools such as Microsoft Power BI, Qlik, and Tableau. AI lowers the skills barrier by automating the highly technical work needed to prepare and analyze data and create and share reports and dashboards.
The Pyramid Decision Intelligence Platform delivers data-driven insights for anyone to make faster, more intelligent decisions. The Pyramid Platform provides instant access to any data, enables automated governed self-service for any person, and serves any analytics need, from the simple to the sophisticated. By uniquely combining Data Prep, Business Analytics, and Data Science with AI guidance in a single environment, the Pyramid Platform reduces cost and complexity while accelerating growth and innovation. This enables a strategic, organization-wide approach to Business Intelligence and Analytics.
Quotes
Bill Clayton, Vice President of Global Partner Sales, Pyramid Analytics: “Channel partnerships are an essential cornerstone of Pyramid’s growth strategy. Our highly productive and effective work with channel partners has forged a host of mutually beneficial relationships that have driven growth for all involved across the UKI. Channel partners are at the core of Pyramid’s business model. The growth and expansion of the company is firmly embedded with our channel partners.”
About Pyramid Analytics
Pyramid is what’s next in analytics. The award-winning Pyramid Decision Intelligence Platform delivers insights for faster, optimized decisions by providing direct access to any data, enabling governed self-service for any person, and meeting any analytics need in a no-code environment. The Pyramid Platform uniquely combines Data Prep, Business Analytics, and Data Science in a single environment with AI guidance, reducing cost and complexity while accelerating growth and innovation. This enables a strategic, enterprise-wide approach to Business Intelligence and Analytics, from the simple to the sophisticated. Schedule a demo.
Pyramid Analytics is incorporated in Amsterdam and has regional headquarters in global innovation and business centers, including London, New York City, and Tel Aviv. Our team lives worldwide because geography should not be a barrier to talent and opportunity. Investors include H.I.G. Growth Partners, Jerusalem Venture Partners (JVP), Sequoia Capital, and Viola Growth. Learn more at Pyramid Analytics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221130005245/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom